PA8545001A1 - Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismas - Google Patents

Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismas

Info

Publication number
PA8545001A1
PA8545001A1 PA20028545001A PA8545001A PA8545001A1 PA 8545001 A1 PA8545001 A1 PA 8545001A1 PA 20028545001 A PA20028545001 A PA 20028545001A PA 8545001 A PA8545001 A PA 8545001A PA 8545001 A1 PA8545001 A1 PA 8545001A1
Authority
PA
Panama
Prior art keywords
triazatetraciclo
hexadeca
same
pentaene
pharmaceutical compositions
Prior art date
Application number
PA20028545001A
Other languages
English (en)
Spanish (es)
Inventor
Lewin Theophilus Wint
Phillip James Johnson
Peter Robert Rose
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8545001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8545001A1 publication Critical patent/PA8545001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
PA20028545001A 2001-05-14 2002-05-14 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismas PA8545001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
PA8545001A1 true PA8545001A1 (es) 2003-09-05

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028545001A PA8545001A1 (es) 2001-05-14 2002-05-14 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismas

Country Status (37)

Country Link
US (1) US6787549B2 (enExample)
EP (1) EP1390366B1 (enExample)
JP (1) JP4137645B2 (enExample)
KR (1) KR20040008175A (enExample)
CN (1) CN1509288A (enExample)
AP (1) AP1429A (enExample)
AR (1) AR035889A1 (enExample)
AT (1) ATE303386T1 (enExample)
BG (1) BG108344A (enExample)
CA (1) CA2446988A1 (enExample)
CZ (1) CZ20032917A3 (enExample)
DE (1) DE60205888T2 (enExample)
DO (1) DOP2002000390A (enExample)
DZ (1) DZ3503A1 (enExample)
EA (1) EA005529B1 (enExample)
EE (1) EE200300557A (enExample)
ES (1) ES2245731T3 (enExample)
GT (1) GT200200081A (enExample)
HR (1) HRP20030911A2 (enExample)
HU (1) HUP0304085A3 (enExample)
IL (1) IL157874A0 (enExample)
IS (1) IS6956A (enExample)
MA (1) MA27021A1 (enExample)
MX (1) MXPA03010365A (enExample)
MY (1) MY134123A (enExample)
NO (1) NO20035035L (enExample)
NZ (1) NZ528209A (enExample)
OA (1) OA12600A (enExample)
PA (1) PA8545001A1 (enExample)
PE (1) PE20021095A1 (enExample)
PL (1) PL366774A1 (enExample)
SK (1) SK13372003A3 (enExample)
TN (1) TNSN03112A1 (enExample)
UA (1) UA73421C2 (enExample)
UY (1) UY27287A1 (enExample)
WO (1) WO2002092597A1 (enExample)
ZA (1) ZA200307234B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410550B1 (en) * 1997-12-31 2002-06-25 Pfizer Inc Aryl fused azapolycyclic compounds
DK1448235T3 (da) * 2001-11-30 2007-07-02 Pfizer Prod Inc Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP2086977A2 (en) * 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphs of nicotinic intermediates
WO2009109651A1 (en) * 2008-03-06 2009-09-11 Medichem, S.A. SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
CA2709774C (en) 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010068181A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
WO2013163917A1 (zh) 2012-04-13 2013-11-07 连云港金康和信药业有限公司 化合物jk12a及其制备
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
CN115968283B (zh) * 2020-03-16 2024-11-22 成都科岭源医药技术有限公司 5-ht3受体调节剂、晶型、制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410550B1 (en) * 1997-12-31 2002-06-25 Pfizer Inc Aryl fused azapolycyclic compounds
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
IL157874A0 (en) 2004-03-28
WO2002092597A1 (en) 2002-11-21
US20030149091A1 (en) 2003-08-07
PE20021095A1 (es) 2002-12-14
JP2004529186A (ja) 2004-09-24
NO20035035D0 (no) 2003-11-13
UA73421C2 (en) 2005-07-15
HUP0304085A2 (en) 2004-04-28
US6787549B2 (en) 2004-09-07
HRP20030911A2 (en) 2004-02-29
GT200200081A (es) 2003-04-22
DE60205888T2 (de) 2006-07-06
DZ3503A1 (enExample) 2002-11-21
SK13372003A3 (sk) 2004-08-03
CZ20032917A3 (cs) 2004-07-14
DOP2002000390A (es) 2003-03-15
EP1390366B1 (en) 2005-08-31
NO20035035L (no) 2003-11-13
TNSN03112A1 (fr) 2005-12-23
OA12600A (en) 2006-06-09
MXPA03010365A (es) 2004-03-16
CN1509288A (zh) 2004-06-30
ZA200307234B (en) 2004-09-16
HUP0304085A3 (en) 2005-09-28
DE60205888D1 (de) 2005-10-06
IS6956A (is) 2003-09-15
EE200300557A (et) 2004-04-15
AR035889A1 (es) 2004-07-21
EA200301120A1 (ru) 2004-02-26
PL366774A1 (en) 2005-02-07
KR20040008175A (ko) 2004-01-28
MY134123A (en) 2007-11-30
NZ528209A (en) 2004-09-24
UY27287A1 (es) 2003-02-28
AP1429A (en) 2005-06-13
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
EP1390366A1 (en) 2004-02-25
JP4137645B2 (ja) 2008-08-20
MA27021A1 (fr) 2004-12-20
BG108344A (bg) 2004-12-30
ES2245731T3 (es) 2006-01-16
AP2002002522A0 (en) 2002-06-30
EA005529B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
PA8545001A1 (es) Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11 .0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismas
DZ3506A1 (fr) Derives de pyrrole utilises comme agents pharmaceutiques
DOP2002000422A (es) Agentes antibacterianos.
HN1999000124A (es) Derivados de pirazol substituido.
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
ECSP034850A (es) Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
CR7333A (es) Forma poliforma de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
ECSP088296A (es) Compuestos terapéuticos
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
CL2004001085A1 (es) Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
ATE274515T1 (de) Pyrazolopyridinderivate
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
PT1385512E (pt) Utilizacao de derivados de piridoindolona para preparacao de medicamentos anticancerigenos
EE05329B1 (et) GlyT-1 inhibiitorid, neid sisaldavad kompositsioonid, nende kasutamine ja nende valmistamise vahehendid
AR032520A1 (es) Compuestos
AR032519A1 (es) Compuestos
PT1345605E (pt) Composicao farmaceutica solida termomoldavel para a libertacao controlada de perindopril
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
ITMI20001053A0 (it) Derivati 2-amminotetralinici otticamente attivi, procedimenti per la loro preparazione e impiego terapeutico delle corrispondenti composizio
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
BR0210099A (pt) Agentes antibacterianos